External Source Analysis
Science & Technology News for New Zealand sciencenownz.co.nz
Making science accessible since 2008
Health › Infectious Disease › Superbugs
Feature

The Superbug Crisis: Are We Running Out of Antibiotics?

Drug-resistant bacteria are killing over a million people a year — and the pipeline of new antibiotics has nearly dried up. Is the medical world prepared for a post-antibiotic era?

[Photo: microscope image of bacteria]
Drug-resistant bacteria have rendered some common infections untreatable with standard antibiotics. (Illustrative image)
1.27M
deaths directly from antibiotic resistance per year globally
0
new antibiotic classes approved between 1962 and 2000
10M
projected annual deaths from AMR by 2050 if unchecked

When Alexander Fleming discovered penicillin in 1928, he warned that misuse could render it useless. Almost a century later, his warning has proven prophetic. Bacteria that once succumbed quickly to a course of amoxicillin are now surviving drugs that doctors considered last resorts just a decade ago.

Antimicrobial resistance — the ability of bacteria to evolve defences against the drugs designed to kill them — is now one of the World Health Organization's top global health threats. Studies show it already kills more people annually than HIV/AIDS or malaria in some regions.

The Golden Age That Ended Too Soon

From the 1940s through the 1970s, pharmaceutical companies introduced dozens of new antibiotic classes. It seemed, for a while, as though medicine had conquered bacterial infection. But scientists now know that every antibiotic use creates selection pressure — it kills susceptible bacteria while leaving resistant ones to multiply and spread their resistance genes.

The global rollout of antibiotics in human medicine, veterinary medicine, and agriculture accelerated this process enormously. And when resistance problems began to emerge in the 1980s, the pharmaceutical industry largely retreated from antibiotic development. Antibiotics, it turned out, were commercially unattractive: they are taken for short courses, they work too well, and governments encourage using them sparingly.

"The pipeline is not empty — but it is dangerously thin. Most drugs in development are modifications of existing classes, not genuinely new mechanisms." — Professor Anna Liu, University of Melbourne Department of Microbiology, in a recent interview with ScienceNow NZ

The Bacteria That Scare Doctors Most

The WHO maintains a list of "priority pathogens" — bacteria for which new treatments are most urgently needed. At the top are carbapenem-resistant bacteria, which can shrug off carbapenems, once considered the heavy artillery of antibiotics. Infections with these organisms can be untreatable with any currently available drug.

In New Zealand, researchers at ESR (the Institute of Environmental Science and Research) track the emergence of resistant organisms in hospitals and the community. While New Zealand's situation is better than many countries, experts say the country is not insulated from global trends — especially given international travel and supply chains.

Agriculture's Role

Roughly 70% of antibiotics consumed globally are used in agriculture — not to treat sick animals, but to promote growth and prevent disease in crowded conditions. Studies show this is a significant driver of resistance, as resistant bacteria in animal populations can transfer resistance genes to bacteria that infect humans.

New Zealand has moved to restrict agricultural antibiotic use in recent years, but critics argue the reforms haven't gone far enough. "We can't keep using antibiotics as a substitute for good farming practice," one researcher told us.

So what can we actually do?
Experts say the solution requires action at every level: individuals completing antibiotic courses as prescribed and not demanding antibiotics for viral infections; doctors following prescribing guidelines more consistently; governments incentivising drug development; and international coordination on surveillance and stewardship. None of these are simple — but all are necessary.

Is There Hope?

There is, cautiously. Phage therapy — using viruses that specifically attack bacteria — is being trialled in cases where antibiotics have failed. Researchers are exploring entirely new mechanisms of antibiotic action. And internationally, push-pull funding models are trying to make antibiotic development commercially viable again.

But scientists warn that the window is narrowing. Every year of inaction sees resistance spread further. The question, as one researcher put it bluntly, is whether we'll solve this problem before the bacteria solve us.